Evidence map›Paper›PMID 38320689›Full record

ArticleExperimental hematology2024

In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric T-cell acute lymphoblastic leukemia xenografts.

Joanna Randall, Kathryn Evans, Ben Watts, Hansen J Kosasih, Christopher M Smith, Eric J Earley, Stephen W Erickson, Emily L Jocoy, Carol J Bult, Beverly A Teicher and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Joanna RandallChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia.
Kathryn EvansChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia.
Ben WattsChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia.
Hansen J KosasihChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia.
Christopher M SmithChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia.
Eric J EarleyRTI International, Research Triangle Park, Research Triangle, NC.
Stephen W EricksonRTI International, Research Triangle Park, Research Triangle, NC.
Emily L JocoyThe Jackson Laboratory, Sacramento, CA.
Carol J BultThe Jackson Laboratory, Bar Harbor, ME.
Beverly A TeicherNational Cancer Institute, Bethesda, MD.
Charles E de BockChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia.
Malcolm A SmithNational Cancer Institute, Bethesda, MD.
Richard B LockChildren's Cancer Institute, Lowy Cancer Research Centre, School of Clinical Medicine, University of New South Wales Medicine & Health, Centre for Childhood Cancer Research, University of New South Wales Sydney, Sydney, NSW, Australia. Electronic address: rlock@ccia.org.au.
Cancer Institute of New South Wales · AUJackson Laboratory · USNational Cancer Institute · USRTI International · US

Funding

Pediatric Preclinical Testing Consortium - LeukemiaU01CA199000 · NCI · UNIVERSITY OF NEW SOUTH WALES · PI Richard B Lock · 2015 to 2026
$4.8M
Pediatric Oncology In Vivo Testing Program Coordinating CenterU24CA263963 · NCI · JACKSON LABORATORY · PI CAROL J BULT, Jeffrey Hsu-Min Chuang · 2021 to 2026
$4.7M
Pediatric Preclinical Testing Consortium: Coordinating Center-Additional PPTC funding extensionU01CA199222 · NCI · RESEARCH TRIANGLE INSTITUTE · PI GATTO, GREGORY J · 2015 to 2021
$2.6M
NCI NIH HHS U01 CA199000NCI NIH HHS U01 CA199222NCI NIH HHS U24 CA263963
6 · The paper itself

Abstract

The overall survival rate of patients with T-cell acute lymphoblastic leukemia (T-ALL) is now 90%, although patients with relapsed T-ALL face poor prognosis. The ubiquitin-proteasome system maintains normal protein homeostasis, and aberrations in this pathway are associated with T-ALL. Here we demonstrate the in vitro and in vivo activity of ixazomib, a second-generation orally available, reversible, and selective proteasome inhibitor against pediatric T-ALL cell lines and patient-derived xenografts (PDXs) grown orthotopically in immunodeficient NOD.Cg-Prkdc

Indexed as

Boron CompoundsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAnimalsChildGlycineHeterograftsHumansMiceMice, Inbred NODMice, SCIDProteasome InhibitorsT-LymphocytesBoron CompoundsGlycineixazomibProteasome Inhibitors

Identifiers

PMID38320689
PMCPMC10978271
OpenAlexW4391533367

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.